Symbols

BRTX

Biorestorative·NASDAQ

--(--)

BRTX fundamentals

BRTX Q3 2025 Earnings

Biorestorative (BRTX) released its earnings on Nov 12, 2025: revenue was 11.80K (YoY -94.96%), missed estimates; EPS was -0.33 (YoY -153.85%), beat estimates.

Revenue / YoY

11.80K

-94.96%

EPS / YoY

-0.33

-153.85%

Report date

Nov 12, 2025

BRTX Earnings Call Summary for Q3,2025

Market Expansion Focus: $63B BioCosmeceuticals opportunity with customizable exosome therapies; direct-to-professional and DTC strategies.
Clinical Milestone: Phase II BRTX-100 enrollment nearing completion; FDA Type B meeting in December for potential accelerated BLA.
Financial Strength: $5.6M cash post-financing; managing losses while investing in growth initiatives.
IP Expansion: Japanese patent for ThermoStem allogeneic stem cell therapy; licensing discussions ongoing.
Resource Allocation: Prioritizing lumbar spine trial; cervical trial on hold for now.

Earnings

EPS

Revenue

Revenue & Expenses

BRTX has released its 2025 Q4 earnings report, with revenue of 19.60K, reflecting a YoY change of -54.73%, and net profit of -3.21M, showing a YoY change of -96.05%. The Sankey diagram below clearly presents BRTX's revenue sources and cost distribution.

Key Indicators

Biorestorative (BRTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Biorestorative (BRTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Biorestorative (BRTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Biorestorative (BRTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown